WallachBeth Capital Announces that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer has entered into securities purchase agreements with several institutional and accredited investors (the “Purchasers”) for the purchase and sale of 990 shares of the Company’s Series B Convertible Preferred Stock (the “Preferred Stock”) and warrants (the “Private Placement Warrants”) to purchase approximately 6.7 million shares of common stock (the “Private Placement”).